Conditional reimbursement context: An economic evaluation including a risk-sharing scheme A hybrid-modeling study that evaluated the clinical outcomes, cost-effectiveness, and budget impact of biologic rheumatoid
Well-known Market Access professionals, Satu Rauhala and Akseli Kivioja, joined ESiOR on August 7th, 2017. Their joint experience is unique: Finnish Pharmaceuticals Pricing Board, pharma industry,
The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a
Multiple sclerosis (MS) progression and the cost-effectiveness analysis of first line disease modifying MS treatments (DMT) in Finland ESiOR studied relapsing-remitting MS (RRMS) progression and
Janne Martikainen, PhD (health economics), Adjunct Professor (economic evaluation of pharmaceuticals) in Turku University and one of ESiOR’s health economists and partners is now also
Development of business and services portfolio Project’s goals are to innovate and develop new business, support business growth and strengthen national and international competitiveness of
ESiOR Ltd takes part in Nordic conference on Real World Data – Collaboration between pharma industry and Academia on November 29-30, 2016, in Helsinki. We
A large proportion of patients with atrial fibrillation (AF) do not attain the treatment targets with traditional warfarin treatment. As a result, they remain at
Many patients with major depressive disorder (MDD) do not have adequate response to the first medical treatment or have adverse effects that lead to treatment
It is time for celebration. ESiOR will participate in International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress in Vienna for the tenth
Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. SpringerPlus 2016;5:1354. Julkaisuluettelo
ESiOR participated in Terveys ja talous -päivät (Finnish seminar on health and economics) and presented a new study on cost-effectiveness of atrial fibrillation treatments “Eteisvärinän
